Substituted purines and oligonucleotide cross-linking
AssigneeIsis Pharmaceuticals, Inc.
InventorsPhillip Dan Cook, Muthiah Manoharan, Kanda S. Ramasamy
Life of this patent
Estimating the term…
Loading patent…
AssigneeIsis Pharmaceuticals, Inc.
InventorsPhillip Dan Cook, Muthiah Manoharan, Kanda S. Ramasamy
Estimating the term…
This invention is directed to novel purine-based compounds for inclusion into oligonucleotides. The compounds of the invention, when incorporated into oligonucleotides are especially useful as "antisense" agents--agents that are capable of specific hybridization with a nucleotide sequence of an RNA. The compounds of the invention may also be used for cross-linking oligonucleotides. Oligonucleotides are used for a variety of therapeutic and diagnostic purposes, such as treating diseases, regulating gene expression in experimental systems, assaying for RNA and for RNA products through the employment of antisense interactions with such RNA, diagnosing diseases, modulating the production of proteins, and cleaving RNA in site specific fashions. The compounds of the invention include novel heterocyclic bases, nucleosides, and nucleotides. When incorporated into oligonucleotides, the compounds of the invention can be useful for modulating the activity of RNA.
A compound having the formula:
A compound having the formula:
A compound having the formula:
A compound having the formula:
A compound having the formula:
An oligonucleotide having at least one nucleotide of the formula:
An oligonucleotide for affecting RNase H cleavage of RNA comprising:
A cross-linked nucleic acid comprising:
The compound 2-amino-N.sub.6 -imidazol-1-yl(propyl)!-9-(2-deoxy-.beta.-D-erythro-pentofuranosyl)adenos ine.
The compound N.sub.6 -imidazol-1-yl(propyl)!-9-(2-deoxy-.beta.-D-erythro-pentofuranosyl)adenos ine.
The compound N.sub.6 -imidazol-4-yl(ethyl)!-9-(2-deoxy-.beta.-D-erythro-pentofuranosyl)adenosi ne.
Dependencies are inferred from the claim text.